Company news
Aptorum Group Limited news in 2021
Aptorum Group Limited's news releases, calls and decks from 2021, newest first.
Aptorum Group Limited Announces Results of 2021 Annual General Meeting of Shareholders
December 2, 2021
Aptorum Group Limited to Hold Annual General Meeting of Shareholders on December 2, 2021
October 18, 2021
Aptorum Group Limited Reports Financial Results and Business Update for the Six Months Ended June 30, 2021
September 14, 2021
Aptorum Group Limited Has Received IND Clearance From the US FDA to Initiate Clinical Trials for Repurposed Small Molecule Drug SACT-1 for the Treatment of Neuroblastoma
September 14, 2021
Aptorum Group Announces Further Positive Interim Results of the Phase 1 Clinical Trial of ALS-4 Targeting Staphylococcus aureus
July 11, 2021
Aptorum Group Announces Positive Interim Phase I Clinical Trial Progress for ALS-4 Targeting Staphylococcus aureus and Positive Pre-IND Progress for SACT-1 Targeting Neuroblastoma
May 23, 2021
Aptorum Group Enters into an Agreement with Exeltis to Develop Aptorum’s Novel Preclinical Candidate Targeting Woman’s Gynecological Conditions
May 5, 2021
Aptorum Group Enters Into Material Transfer and Exclusive Option-To-License Agreement with Yale University for Its Novel Immunomodulators Potentially Targeting Autoimmune and Oncology Diseases
April 21, 2021
Aptorum Group Announces Dosing First Human Subject in a Phase I Clinical Trial of ALS-4, a First-in-Class Small Molecule Drug Designed to Treat Infections caused by Staphylococcus Aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
March 30, 2021
Aptorum Group Receives Clearance from Health Canada to Initiate a Phase 1 Clinical Trial for ALS-4, a Small Molecule Drug for Infections Caused by Staphylococcus aureus including Methicillin-resistant Staphylococcus aureus (MRSA)
January 19, 2021